What is Synlogic?
Synlogic is a biotechnology pioneer dedicated to the transformative potential of synthetic biology in medicine. The company utilizes a proprietary, modular platform for microbial engineering to design Synthetic Biotic medicines. These engineered therapeutics are specifically designed to target the underlying biology of disease, offering novel treatment modalities for metabolic disorders such as phenylketonuria (PKU), enteric hyperoxaluria, and homocystinuria. Beyond its metabolic focus, the firm is actively cultivating a diverse portfolio of partner-able assets within the immunology space, positioning itself as a leader in the next generation of precision medicine.
How much funding has Synlogic raised?
Synlogic has raised a total of $283.9M across 6 funding rounds:
Series A
$34.4M
Series B
$40M
Series C
$42M
Stock Offering
$57.5M
Stock Offering
$30M
Corporate Investment
$80M
Series A (2014): $34.4M with participation from NEA, Bill & Melinda Gates Foundation, and Atlas Ventures
Series B (2016): $40M led by Deerfield Management Company, Atlas Ventures, NEA, and OrbiMed
Series C (2017): $42M supported by Deerfield, CLI Ventures, Aju IB Investment, Arctic Aurora LifeScience, Ally Bridge Group, Rock Springs Capital, Perceptive Advisors, OrbiMed, Atlas Ventures, and NEA
Stock Issuance/Offering (2018): $57.5M featuring Undisclosed
Stock Issuance/Offering (2018): $30M backed by Undisclosed
Corporate Investment (2019): $80M with participation from Ginkgo Bioworks
Key Investors in Synlogic
Atlas Ventures
Atlas Venture is a pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains.
Deerfield Management Company
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem.
What's next for Synlogic?
With significant capital reserves secured through its history of financing, Synlogic is well-positioned to accelerate its clinical pipeline and deepen its strategic partnerships. The focus moving forward will likely center on the validation of its Synthetic Biotic platform in human trials and the expansion of its immunological research. As the company matures, the integration of its modular engineering approach with broader therapeutic applications will be critical in maintaining its competitive advantage. Investors will be monitoring the company's ability to translate its sophisticated microbial engineering into scalable, regulatory-approved medical solutions that address significant unmet clinical needs.
See full Synlogic company page
